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Introduction {#sec001}
============

Postural tachycardia syndrome, inappropriate sinus tachycardia (IST) and vasovagal syncope are common diseases of the autonomic nervous system in children and adults. Working criteria for diagnoses and recommendations on their assessment and management were published in a 2015 paper entitled "Heart Rhythm Society Consensus Statement on the Diagnosis and Treatment of Postural Tachycardia Syndrome, Inappropriate Sinus Tachycardia, and Vasovagal Syncope" \[[@pone.0238139.ref001]\]. Representatives of the Pediatric and Congenital Electrophysiology Society were engaged in this paper; however, the incidence, diagnostic criteria, and pharmacotherapy of IST in children remain ill-defined. Most patients develop the first clinical symptoms as adolescents during maturation of their autonomic nervous system. Hence adolescence appears to be a vulnerable phase in the development of these diseases and offers a potential window of opportunity for therapeutic interventions.

Over the last 20 years, we have used Holter ECG monitoring as a diagnostic tool to analyze autonomic dysfunction and monitor pharmacotherapy in childhood. Our publications focused on basic pathophysiology and new therapeutic approaches:

1.  **Heart Failure:** Beta blocker therapy for heart failure in infants, children, and adults with congenital heart disease \[[@pone.0238139.ref002]\].

2.  **Early Life Stress:** The impact of early life stress on height and neurodevelopmental impairment \[[@pone.0238139.ref003]\].

3.  **Attention Deficit Disorder**: Stress and cognitive dysfunction in children \[[@pone.0238139.ref004]\].

4.  **Nutritional Disorders:** The impact of nutrition on the autonomic nervous system \[[@pone.0238139.ref005]\].

5.  **Omega-3 fatty acid supplementation:** Effects on heart rate variability (HRV) in children with autonomic dysfunction \[[@pone.0238139.ref006]\].

In the current analysis, we test the hypothesis that an elevated mean 24-h heart rate, known as inappropriate sinus tachycardia, is the common final pathway of a group of children with autonomic dysfunction who had a high cardiovascular risk in later life. We calculate the risk of IST in eight patient groups and the effect of pharmacotherapy on this risk.

Swedish register data clearly show that an elevated resting heart rate in adolescence is an important cardiovascular risk factor for later all-cause mortality, most commonly due to the higher risk of heart failure \[[@pone.0238139.ref007]\]. We attempt to differentiate the effect of an elevated heart rate from elevated blood pressures. Finally, we test whether omega-3-fatty acid supplementation effectively reduces the mean 24-h heart rates of children with inappropriate sinus tachycardia.

Materials and methods {#sec002}
=====================

Patients {#sec003}
--------

Retrospective analysis of patient data was approved by the ethical board of our state's medical chamber (Landesärztekammer Baden Württemberg). First Data of this retrospective analysis were recently published \[[@pone.0238139.ref008]\]. All patients undergoing any kind of treatment, phamacologic as stimulant therapy or nutritional intervention as omega-3 fatty acid supplementation gave oral informed consent for data analysis, which was documented in the patient charts. Equally oral informed consent was achieved from patients with inappropriate sinus tachycardia. Of course data analysis was skipped if patient consent was denied.

Based upon our hypotheses about autonomic dysfunction in childhood, we analyzed 24-h HRV in 479 children with a mean age of 13.7 ± 2.1 years, who were referred to the outpatient clinic in the Pediatrics Department of the Caritas Hospital, in Bad Mergentheim, Germany, between 2005 and 2019.

For this analysis, we included the initial Holter ECG of each patient, in cases where many of our therapeutic decisions were based upon HRV monitoring as a target of pharmacotherapy and nutritional interventions. From available data of first visits, most patients had no pharmacotherapy, whereas some patients in groups 1/2/4 had received long-term pharmacotherapy. For further analysis, we stepwise excluded groups who had a known impact on the autonomic nervous system (Surgically-treated Congenital Heart Disease\>Attention Deficit Disorder with/without Hyperactivity\>Anorexia Nervosa\>Short Stature\>Constitutional Thinness\>Obesity\>Hypertension\>Pre Hypertension\>Healthy Control). After hierarchical exclusion of these patient groups, a group of 66 children remains that should be autonomic healthy to the best of our knowledge. These data came from patients who attended our outpatient clinic for exclusion of cardiac arrhythmia or heart defects. For descriptive statistics as shown in Tables [1](#pone.0238139.t001){ref-type="table"} and [2](#pone.0238139.t002){ref-type="table"} we used the following groups:

1.  **Surgically-treated Congenital Heart Disease** (N = 55). Pharmacotherapy: Beta blocker = 7, Angiotensin-converting enzyme inhibitor and Angiotensin receptor antagonists = 4, Digoxin = 3, Calcium Antagonist = 1.

2.  **Attention Deficit Disorder with/without Hyperactivity** (N = 86). Pharmacotherapy: Methylphenidate = 69, Atomoxetine = 7, Amphetamine = 3.

3.  **Anorexia Nervosa** (N = 34). No pharmacotherapy.

4.  **Short Stature** (N = 15). Pharmacotherapy: Growth Hormone = 3, Beta blocker = 1.

5.  **Constitutional Thinness** (N = 20). No pharmacotherapy.

6.  **Obesity** (N = 130). Pharmacotherapy: Beta blocker = 1, Angiotensin-converting enzyme-inhibitor = 1.

7.  **Hypertension** (N = 53). No pharmacotherapy at baseline.

8.  **Pre-hypertension** (N = 13) No pharmacotherapy.

9.  **Healthy Control** (N = 66) No pharmacotherapy.

10.1371/journal.pone.0238139.t001

###### Anthropometric measurements and patient groups.

![](pone.0238139.t001){#pone.0238139.t001g}

                                   N     Age \[Yrs\]   Height \[cm\]                                     Height Perc. \[%\]                               Weight \[kg\]                                     BMI \[kg/m2\]                                     BMI Perc. \[%\]                                  Syst. BP \[mmHg\]                                  Syst. BP Perc \[%\]                               Diast. BP \[mmHg\]                                Diast. BP Perc. \[%\]
  -------------------------------- ----- ------------- ------------------------------------------------- ------------------------------------------------ ------------------------------------------------- ------------------------------------------------- ------------------------------------------------ -------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  **Healthy control**              66    13.8 ± 2.3    161.4 ± 11.7                                      55.3 ± 26.5                                      51.5 ± 11.5                                       19.5 ± 2.7                                        49.4 ± 27.5                                      111.2 ± 9.4                                        54.0 ± 25.8                                       62.5 ± 8.1                                        43.6 ± 22.2
  **Congenital heart defect**      55    13.9 ± 2.3    155.7 ± 14.8                                      39.5 ± 32.8                                      50.8 ± 18.3                                       20.5 ± 5.2                                        52.2 ± 31.9                                      117.0 ± 13.5                                       68.2 ± 3 0.4                                      60.7 ± 10.7                                       40.6 ± 28.7
  **Attention deficit disorder**   86    13.2 ± 2.0    157.4 ± 12.2                                      43.7 ± 28.6                                      52.2 ± 17.4                                       20.7 ± 5.3                                        54.3 ± 33.6                                      121.1 ± 13.6[a](#t001fn003){ref-type="table-fn"}   76.1 ± 25.6[a](#t001fn003){ref-type="table-fn"}   65.2 ± 11.1                                       53.3 ± 27.6
  **Anorexia nervosa**             34    14.7 ± 2.2    163.6 ± 8.1                                       49.1 ± 28.5                                      39.4 ± 5.7[a](#t001fn003){ref-type="table-fn"}    14.6 ± 1.3[a](#t001fn003){ref-type="table-fn"}    2.3 ± 5.8[a](#t001fn003){ref-type="table-fn"}    101.8 ± 11.1[a](#t001fn003){ref-type="table-fn"}   29.6 ± 27.8[a](#t001fn003){ref-type="table-fn"}   61.4 ± 8.6                                        37.9 ± 23.9
  **Short stature**                15    14.5 ± 1.9    148.8 ± 8.6[a](#t001fn003){ref-type="table-fn"}   8.4 ± 15.9[a](#t001fn003){ref-type="table-fn"}   52.0 ± 21.5                                       23.5 ± 10.5                                       57.9 ± 39.8                                      118.4 ± 17.8                                       72.9 ± 27.6                                       64.08.6                                           53.5 ± 21.0
  **Obesity**                      130   13.3 ± 2.1    161.8 ± 10.5                                      62.5 ± 28.7                                      82.2 ± 20.1[a](#t001fn003){ref-type="table-fn"}   31.1 ± 5.0[a](#t001fn003){ref-type="table-fn"}    98.8 ± 1.4[a](#t001fn003){ref-type="table-fn"}   128.8 ± 13.7[a](#t001fn003){ref-type="table-fn"}   86.9 ± 18.8[a](#t001fn003){ref-type="table-fn"}   64.2 ± 12.8                                       48.5 ± 30.7
  **Constitutional thinness**      20    13.8 ± 1.7    160.8 ± 10.9                                      46.2 ± 25.3                                      38.7 ± 7.0                                        14.8 ± 11.8[a](#t001fn003){ref-type="table-fn"}   1.9 ± 1.7[a](#t001fn003){ref-type="table-fn"}    108.2 ± 11.5                                       45.6 ± 35.3                                       59.4 ± 7.7                                        36.2 ± 25.0
  **Hypertension**                 53    13.8 ± 2.0    163.0 ± 12.1                                      52.6 ± 22.7                                      56.3 ± 13.9                                       20.9 ± 2.9                                        63.3 ± 26.1                                      139.1 ± 11.0[a](#t001fn003){ref-type="table-fn"}   98.6 ± 1.3[a](#t001fn003){ref-type="table-fn"}    69.7 ± 10.2[a](#t001fn003){ref-type="table-fn"}   63.8 ± 26.4[a](#t001fn003){ref-type="table-fn"}
  **Pre-hypertension**             13    14.2 ± 2.0    162.7 ± 9.8                                       45.9 ± 31.3                                      54.8 ± 11.6                                       20.5 ± 2.8                                        57.1 ± 29.7                                      126.4 ± 4.2[a](#t001fn003){ref-type="table-fn"}    92.7 ± 1.6[a](#t001fn003){ref-type="table-fn"}    72.5 ± 7.3[a](#t001fn003){ref-type="table-fn"}    72.1 ± 19.9a

Unpaired t-test between healthy control and eight patient groups

BMI = body mass index; Perc. = percentile; BP = blood pressure.

^a^P-value \< 0.001.

10.1371/journal.pone.0238139.t002

###### Patient groups and heart rate variability.
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                                   HR                                                HR day                                            HR night                                          SDNN                                               RMSSD                                             pNN50                                             TP 24 h       VLF 24 h      LF 24 h                                          HF 24 h                                         HF/LF 24 h
  -------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ------------- ------------- ------------------------------------------------ ----------------------------------------------- -------------
  **Healthy control**              78.2 ± 8.4                                        87.5 ± 10.1                                       66.2 ± 8.7                                        166.9 ± 51.9                                       49.2 ± 15.4                                       28.6 ± 13.2                                       6352 ± 3527   3475 ± 2529   1709 ± 741                                       1078 ± 888                                      0.61 ± 0.27
  **Congenital heart defect**      81.1 ± 12.4                                       87.8 ± 12.9                                       70.5 ± 13.4                                       144.8 ± 53.5                                       39.2 ± 18.4[a](#t002fn003){ref-type="table-fn"}   19.5 ± 14.9[a](#t002fn003){ref-type="table-fn"}   5417 ± 4843   3209 ± 3521   1287 ± 913                                       825 ± 1271                                      0.59 ± 0.36
  **Attention deficit disorder**   87.9 ± 9.5c                                       98.3 ± 10.1c                                      71.6 ± 13.6                                       153.6 ± 42.6                                       36.1 ± 13.4[c](#t002fn005){ref-type="table-fn"}   17.9 ± 12.4[c](#t002fn005){ref-type="table-fn"}   4573 ± 2872   2670 ± 1995   1239 ± 692[b](#t002fn004){ref-type="table-fn"}   572 ± 363[a](#t002fn003){ref-type="table-fn"}   0.48 ± 0.23
  **Anorexia nervosa**             64.1 ± 12.9[c](#t002fn005){ref-type="table-fn"}   72.5 ± 15.9[c](#t002fn005){ref-type="table-fn"}   49.4 ± 9.49[c](#t002fn005){ref-type="table-fn"}   252.9 ± 70.4[c](#t002fn005){ref-type="table-fn"}   62.5 ± 19.3[c](#t002fn005){ref-type="table-fn"}   38.2 ± 14.9a                                      7933 ± 3587   4748 ± 2722   1905 ± 802                                       1235 ± 511                                      0.7 ± 0.24
  **Short stature**                87.9 ± 8.9                                        93.5 ± 7.3a                                       72.7 ± 9.1                                        130.1 ± 48.4                                       32.6 ± 12.7[c](#t002fn005){ref-type="table-fn"}   16.6 ± 10.5                                       4585 ± 2812   2512 ± 1726   1251 ± 717                                       722 ± 721                                       0.54 ± 0.29
  **Obesity**                      85.5 ± 9.4[c](#t002fn005){ref-type="table-fn"}    93.9 ± 9.9                                        74.1 ± 10.1[c](#t002fn005){ref-type="table-fn"}   138.1 ± 38.4[b](#t002fn004){ref-type="table-fn"}   39.8 ± 13.9[c](#t002fn005){ref-type="table-fn"}   20.2 ± 12.4[c](#t002fn005){ref-type="table-fn"}   4975 ± 3562   2703 ± 2003   1277 ± 765[b](#t002fn004){ref-type="table-fn"}   863 ± 1157                                      0.63 ± 0.36
  **Constitutional thinness**      83.2 ± 8.2                                        90.4 ± 8.8                                        70.6 ± 10.1                                       152.8 ± 35.9                                       39.6 ± 13.5                                       20.1 ± 11.5                                       5668 ± 2825   3169 ± 2204   1468 ± 622                                       865 ± 548                                       0.63 ± 0.41
  **Hypertension**                 81.7 ± 12.4                                       91.4 ± 12.2                                       70.2 ± 11.8                                       156.8 ± 53.83                                      42.9 ± 16.4                                       23.0 ± 13.0                                       6170 ± 4455   3829 ± 3518   1546 ± 795                                       719 ± 343                                       0.48 ± 0.17
  **Pre-hypertension**             77.2 ± 9.5                                        84.7 ± 9.4                                        67.3 ± 8.8                                        167.3 ± 30.5                                       50.8 ± 10.9                                       30.7 ± 10.5                                       6541 ± 2625   3776 ± 1938   1684 ± 596                                       992 ± 369                                       0.61 ± 0.22

HR: heart rate; SDNN: standard deviation of all NN intervals; RMSSD: the square root of the mean of the sum of the squares of differences between adjacent NN intervals; pNN50: number of pairs of adjacent NN intervals differing by more than 50 ms divided by the total number of all NN intervals; TP: total power; VLF: very low-frequency power; LF: low-frequency power; HF: high-frequency power; HF/LF: Ratio HF to LF.

Unpaired t-test between healthy control and eight patient groups

^a^P-value \< 0.05.

^b^P-value \< 0.01.

^c^P-value \< 0.001.

Seven otherwise healthy children had an IST due to different somatoform disorders. These children could not be assigned to any of the groups and were not included in the descriptive statistics but were included in the omega-3 fatty acid supplementation analysis.

However, some patients met several group criteria that would be lost for further analysis. For risk calculation of an inappropriate sinus tachycardia, every single diagnosis of each patient was assigned to the 8 diagnosis groups. In summary we include 595 diagnosis of the 479 children.

24-h ECG and analysis of heart rate variability {#sec004}
-----------------------------------------------

Fundamental to every HRV data analysis is a group of successive normal RR intervals in sinus rhythm over a period of 24 h. In HVR these are called NN intervals to distinguish them from the RR intervals in cardiac arrhythmia. Measurement and interpretation of HRV parameters in the current sample were standardized according to the Task Force Guidelines \[[@pone.0238139.ref009]\]. Cardiac autonomic functioning was measured by 24-h Holter 12-bit digital ECG (Reynolds Pathfinder II, Spacelabs, Germany; 1024 scans/sec). Day- and nighttime periods were defined according to patient protocols. All Holter recordings were reviewed by the same experienced cardiologists (RB and CW) and were edited to validate the system's QRS labeling. Measures of HRV were calculated employing only NN intervals. QRS-complexes classified as noise were excluded from the data. A minimum of 23 h of analyzable data and minimum of 95% of analyzable NN intervals were required for data to be included. For time domain measures, mean NN interval, resulting heart rate, and HRV parameters outlined below were calculated.

For didactic reasons, in this study, we focused on the statistical analysis of the following four parameters:

1.  **Heart rate:** The easiest, but very important, HRV parameter is the average sinus rhythm heart rate, since all other parameters are significantly affected by the heart rate.

2.  **Standard deviation of all normal NN intervals in a time frame (SDNN):** This global HRV parameter represents the overall variability of the autonomic nervous system.

3.  **Square root of the arithmetic mean of the squared deviation of successive normal NN intervals in a time frame (rMSSD):** This parameter is mainly influenced by the parasympathetic nervous system.

4.  **Number of pairs of adjacent NN intervals differing by more than 50 ms, divided by the total number of all NN intervals, multiplied by 100 (pNN50):** This parameter is mainly influenced by the parasympathetic nervous system.

For frequency domain measures, beat-to-beat fluctuations were transformed to the frequency domain using Fast Fourier Transformation. Spectral power was determined over three frequency regions of interest: very low frequency (VLF, \< 0.04 Hz), low frequency (LF, 0.04--0.15 Hz), and high frequency (HF, 0.15--0.4 Hz) with derived HF/LF ratios.

Pharmacotherapy and nutritional supplements {#sec005}
-------------------------------------------

Many patients received pharmacotherapy (e.g., psychostimulants, or growth hormones), others received nutritional intervention (e.g., nutritional refeeding in anorexia nervosa, or omega-3 fatty acid supplementation) with published effects on HRV \[[@pone.0238139.ref006]\]. In the current analysis we tested the effect of methylphenidate treatment on 24-h HRV in 19 children with a mean age of 11.4 ± 2.6 years (18 boys, 1 girl). The data was based on two Holter ECGs over a mean interval of 283 days after starting methylphenidate (N = 11) or ceasing an ongoing therapy (N = 8). All children received an extended-release formulation, 26% with a low dose immediate-release starter in the morning. The extended-release dosage was low (\<0.5 mg/kg MPH) in 52.6%, intermediate (0.5 mg/kg to 0.9 mg/kg MPH) in 31.6%, and high (\>0.9 mg/kg MPH) in 15.8% of the children.

After we realized that omega-3 fatty acid supplementation has an impact on reduced heart rate variability, 145 patients and/or parents decided for omega-3-fatty acid supplementation and a Holter ECG control 196 days later as an average in the last seven years. A group of 29 adolescents had sinus tachycardia \> 95 bpm and was analyzed for this publication. The other 45 patients and or parents with sinus tachycardia \> 95 bpm did not decide for omega-3-fatty acid supplementation or received a pharmacotherapy most of all with a beta blocker in children with hypertension or congenital heart disease. To exclude a selection bias between patients with inappropriate sinus tachycardia who got omega-3-fatty acid supplementation (N = 29) and those who received no supplements (N = 45), we compare all the parameters using a student t-test and found no significant difference (for example mean heart rate 99.4 ± 4.9 versus 99.8 ± 5.0 bpm), except a slightly lower diastolic blood pressure percentile in the omega-3-fatty acid supplementation group (46.6 ± 25.4% versus 59.9 ± 25.9%, p = 0,032).

If the supplementation was not covered by health insurance, patients purchased different products delivering 1--2 g fish oil per day from a retail store. The following dose recommendations were given: Children up to 8 years old should receive at least 400 mg Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) as a suspension per day. Children who were able to swallow capsules should receive at least 800 mg EPA and DHA per day.

Blood pressure {#sec006}
--------------

For blood pressure measurements we used oscillometric (automated) blood pressure measurement devices (Bionics Sentry™, South Korea), which have rapidly replaced sphygmomanometers in clinical practice. These devices are more ecologically friendly, easier to use, and eliminate potential sources of bias. During Bionics Sentry™ measurement, inflation is driven by a pumping system and deflation is driven by an electromagnetic control valve that allows rapid air release. Records are digitally displayed as systolic- and diastolic blood pressure, and heart rate. The internal bladder (inflatable area) of the cuff must encircle 90--100% of the circumference of the upper arm.

Norms for childhood blood pressure among normal-weight children (body mass index \< 85th percentile, based on Centers for Disease Control and Prevention guidelines) as a function of age, sex, and height, were established using data from 49,967 children, included in the database of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents \[[@pone.0238139.ref010]\]. Blood pressure percentiles and the deviation from normal (z-score) values were calculated.

Statistical analysis {#sec007}
--------------------

Data were anonymized before accessing them for statistical analysis. Data were expressed as mean ± standard deviation. As most variables exhibited a normal distribution, between-group differences were assessed using parametric statistics. The study population was divided into eight diagnosis groups and one healthy control group. One-way analysis of variance was used to compare the differences between the healthy control group and the patient groups (Tables [1](#pone.0238139.t001){ref-type="table"} and [2](#pone.0238139.t002){ref-type="table"}). We used a paired student t-test to analyze the effect of methylphenidate and omega-3-fatty acid supplementation on HRV (Tables [3](#pone.0238139.t003){ref-type="table"} and [4](#pone.0238139.t004){ref-type="table"}). For risk stratification according to the different diagnosis groups we used a binary regression analysis ([Table 5](#pone.0238139.t005){ref-type="table"}). Significant group differences were anticipated if the p-value was \< 0.05. Data with significant bivariate correlations were used for linear regression analysis ([Table 6](#pone.0238139.t006){ref-type="table"} and [S1 Table](#pone.0238139.s001){ref-type="supplementary-material"}). All analyses were performed using IBM SPSS Statistics software, Version 25 (IBM Corp. IBM SPSS Statistics for Windows, Version 25.0, Armonk, NY, USA).

10.1371/journal.pone.0238139.t003

###### Methylphenidate (MPH) treatment and heart rate variability.

![](pone.0238139.t003){#pone.0238139.t003g}

  Patients (N = 19)                   24-h heart rate variability    Day time      Night time                                                                                                                                             
  ----------------------------------- ------------------------------ ------------- ------------- ------------- -------------------------------------------------- ------- ------------- ------------------------------------------------- -------
  **Mean heart rate \[bpm\]**         91.3 ± 7.5                     91.9 ± 8.0    0.771         96.0 ± 8.3    101.8 ± 10.8[a](#t003fn003){ref-type="table-fn"}   0.02    86.7 ± 9.7    82.4 ± 9.0                                        0.081
  **RMSSD \[ms\]**                    32.5 ± 12.50                   37.1 ± 17.8   0.053         29.8 ± 10.4   28.2 ± 12.1                                        0.287   35.1 ± 16.5   45.8 ± 24.3[b](#t003fn004){ref-type="table-fn"}   0.004
  **pNN50 \[%\]**                     11.8 ± 8.4                     14.1 ± 9.6    0.106         9.9 ± 6.4     8.7 ± 6.7                                          0.238   13.7 ± 11.8   19.4 ± 13.3[a](#t003fn003){ref-type="table-fn"}   0.013
  **Total power \[ms**^**2**^**\]**   3812 ± 2021                    4246 ± 2396   0.344         3798 ± 2059   3857 ± 24367                                       0.887   3811 ± 2393   4640 ± 2545                                       0.125
  **VLF power \[ms**^**2**^**\]**     2357 ± 1370                    2534 ± 1836   0.631         2437 ± 1444   2425 ± 1957                                        0.974   2264 ± 1692   2653 ± 1852                                       0.369
  **LF power \[ms**^**2**^**\]**      981 ± 608                      1165 ± 611    0.060         955 ± 570     1050 ± 571                                         0.215   1005 ± 677    1278 ± 723[a](#t003fn003){ref-type="table-fn"}    0.04
  **HF power \[ms**^**2**^**\]**      416 ± 223                      490 ± 290     0.195         348 ± 211     330 ± 202                                          0.607   483 ± 302     647 ± 431                                         0.069
  **HF/LF Ratio**                     0.48 ± 0.27                    0.62 ± 0.35   0.968         0.42 ± 0.26   0.41 ± 0.21                                        0.521   0.81 ± 0.34   0.83 ± 0.38                                       0.853

SDNN: standard deviation of all NN intervals; RMSSD: the square root of the mean of the sum of the squares of differences between adjacent NN intervals; pNN50: number of pairs of adjacent NN intervals differing by more than 50 ms divided by the total number of all NN intervals; TP: total power; VLF: very low-frequency power; LF: low-frequency power; HF: high-frequency power; MPH: methylphenidate treatment.

Paired t-test between baseline and methylphenidate treatment

^a^P-value \< 0.05.

^b^P-value \< 0.01.

10.1371/journal.pone.0238139.t004

###### Effect of Omega-3-fatty acid supplementation on heart rate variability in 29 adolescents with inappropriate sinus tachycardia.
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   Patients (N = 29)                  24-h heart rate variability    Day time                                          Night time                                                                                                                                            
  ----------------------------------- ------------------------------ ------------------------------------------------- ------------- ------------- ------------------------------------------------- ------- ------------- ------------------------------------------------- ---------
  **Mean heart rate \[bpm\]**         99.4 ± 4.9                     90.1 ± 7.7[c](#t004fn005){ref-type="table-fn"}    \<0.001       105.0 ± 7.2   98.4 ± 7.7[c](#t004fn005){ref-type="table-fn"}    0.003   87.5 ± 9.9    75.8 ± 6.0[c](#t004fn005){ref-type="table-fn"}    \<0.001
  **RMSSD \[ms\]**                    22.6 ± 7.9                     31.8 ± 12.6[c](#t004fn005){ref-type="table-fn"}   \<0.001       21.6 ± 10.5   27.1 ± 12.0[a](#t004fn003){ref-type="table-fn"}   0.018   34.4 ± 24.0   47.1 ± 26.4[a](#t004fn003){ref-type="table-fn"}   0.011
  **pNN50 \[%\]**                     7.7 ± 6.4                      13.3 ± 10.7[b](#t004fn004){ref-type="table-fn"}   0.003         5.3 ± 5.1     8.8 ± 7.3[a](#t004fn003){ref-type="table-fn"}     0.02    11.7 ± 13.0   22.1 ± 17.8[b](#t004fn004){ref-type="table-fn"}   0.002
  **Total power \[ms**^**2**^**\]**   2587 ± 1641                    3522 ± 2206[b](#t004fn004){ref-type="table-fn"}   0.006         2292 ± 2027   3259 ± 2344[b](#t004fn004){ref-type="table-fn"}   0.002   3227 ± 2852   4435 ± 3323[a](#t004fn003){ref-type="table-fn"}   0.043
  **VLF power \[ms**^**2**^**\]**     1337 ± 727                     1870 ± 1348[a](#t004fn003){ref-type="table-fn"}   0.014         1115 ± 846    1758 ± 1679[b](#t004fn004){ref-type="table-fn"}   0.007   1753 ± 1536   2274 ± 1913                                       0.117
  **LF power \[ms**^**2**^**\]**      689 ± 474                      919 ± 586[b](#t004fn004){ref-type="table-fn"}     0.008         635 ± 401     856 ± 482[b](#t004fn004){ref-type="table-fn"}     0.003   851 ± 1001    1115 ± 1001                                       0.054
  **HF power \[ms**^**2**^**\]**      435 ± 561                      599 ± 613[a](#t004fn003){ref-type="table-fn"}     0.01          374 ± 794     470 ± 723[a](#t004fn003){ref-type="table-fn"}     0.045   552 ± 651     900 ± 676[a](#t004fn003){ref-type="table-fn"}     0.027
  **HF/LF Ratio**                     0.56 ± 0.39                    0.59 ± 0.36                                       0.559         0.41 ± 0.42   0.46 ± 0.39                                       0.376   0.68 ± 0.37   0.81 ± 0.45                                       0.164

SDNN: standard deviation of all NN intervals; RMSSD: the square root of the mean of the sum of the squares of differences between adjacent NN intervals; pNN50: number of pairs of adjacent NN intervals differing by more than 50 ms divided by the total number of all NN intervals; TP: total power; VLF: very low-frequency power; LF: low-frequency power; HF: high-frequency power; Omega-3-FA: omega-3-fatty acid supplementation.

Paired t-test between baseline and omega-3-Fatty Acid Supplementation

^a^P-value \< 0.05.

^b^P-value \< 0.01.

^c^P-value \< 0.001.

10.1371/journal.pone.0238139.t005

###### Binary regression analysis.
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                               Regression coefficentB   Standard Error   Wald     Significance   Exp(B)   95% Confidence interval EXP(B)   
  ---------------------------- ------------------------ ---------------- -------- -------------- -------- -------------------------------- -------
  Sex (male = 1)               -0,524                   0,294            3,186    0,074          0,592    0,333                            1,053
  Congenital Heart Disease     0,306                    0,461            0,441    0,507          1,358    0,55                             3,353
  Attention Deficit Disorder   1,265                    0,335            14,297   0              3,543    1,839                            6,826
  Anorexia Nervosa             -1,191                   1,051            1,285    0,257          0,304    0,039                            2,382
  Short Stature                0,637                    0,485            1,722    0,189          1,891    0,73                             4,897
  Const. Thinness              -0,11                    0,669            0,027    0,87           0,896    0,241                            3,325
  Obesity                      0,359                    0,312            1,322    0,25           1,431    0,777                            2,638
  Hypertension                 0,724                    0,311            5,431    0,02           2,062    1,122                            3,79
  Pre Hypertension             0,918                    0,453            4,099    0,043          2,503    1,03                             6,084

10.1371/journal.pone.0238139.t006

###### Linear regression analysis: Impact of age, height, body mass index, and heart rate variability on the systolic blood pressure.

![](pone.0238139.t006){#pone.0238139.t006g}

  Dependent variable: systolic blood pressure percentile   Unstandardized coefficients   Standardized coefficients   T        Sig.             
  -------------------------------------------------------- ----------------------------- --------------------------- -------- -------- ------- -------
  **Time domain analysis: R^2^ = 0.265**                   (Constant)                    101.293                     10.533            9.616   0.000
  Height SDS                                               −0.123                        0.161                       −0.032   −0.761   0.447   
  BMI SDS                                                  6.465                         0.745                       0.385    8.678    0.000   
  Age                                                      −0.173                        0.637                       −0.012   −0.272   0.786   
  NN 24h                                                   −0.053                        0.015                       −0.240   −3.614   0.000   
  rMSSDs 24h                                               −0.285                        0.129                       −0.218   −2.208   0.028   
  SDNN 24h                                                 0.337                         0.115                       0.277    2.931    0.004   
  **Frequency domain analysis: R^2^ = 0.256**              (Constant)                    109.261                     11.024            9.911   0.000
  Height SDS                                               −0.096                        0.163                       −0.025   −0.591   0.555   
  BMI SDS                                                  6.470                         0.753                       0.385    8.588    0.000   
  Age                                                      0.000                         0.635                       0.000    0.001    0.999   
  NN 24h                                                   −0.059                        0.014                       −0.268   −4.306   0.000   
  TP 24h                                                   0.002                         0.007                       0.204    0.237    0.813   
  VLF 24h                                                  −0.001                        0.007                       −0.110   −0.180   0.857   
  LF 24h                                                   0.002                         0.008                       0.046    0.236    0.814   
  HF 24h                                                   −0.003                        0.008                       −0.087   −0.386   0.699   
  HF/LF 24h                                                0.392                         0.619                       0.027    0.633    0.527   

Results {#sec008}
=======

The anthropometric data are displayed in [Table 1](#pone.0238139.t001){ref-type="table"}. Patients in the nine groups were all of comparable age. By definition the healthy control group patients had normal height, weight, body mass index, systolic and diastolic blood pressures. According to the group definitions mean height, weight, and body mass index were significantly different in the short stature, obesity, anorexia nervosa, and constitutional thinness groups. Systolic/diastolic blood pressures were hypertensive in the hypertension (≥95th percentile) and pre-hypertension (≥90th percentile) groups. In addition to these expected results, the following significant differences compared to the healthy control group were noticeable in the patient groups:

1.  Obese children and children with attention deficit disorder had significantly hypertensive systolic blood pressures on average.

2.  Children with anorexia nervosa had significantly reduced systolic blood pressures on average.

The HRV data are displayed in [Table 2](#pone.0238139.t002){ref-type="table"}. Children with attention deficit disorder had significantly elevated heart rates on average by day. Obese children had significantly elevated heart rates at night. Children with anorexia nervosa had significantly lower heart rates both day and night. Higher heart rates in obese adolescents were associated with a lower global HRV SDNN. Lower heart rates in adolescents with anorexia nervosa were associated with higher global HRV SDNN.

Significantly lower pNN50 and RMSSD values in adolescents with congenital heart defects, attention deficit disorder, and obesity may indicate a lower vagus activity, whereas significantly higher pNN50 and RMSSD values in adolescents with anorexia nervosa may indicate a higher vagus activity. However, these interpretations were not supported by high-frequency power data that were only significantly reduced in children with attention deficit disorder. Changes in high-frequency power were accompanied by concordant changes in low-frequency power, whereas the HF/LF ratio remained within the same range in all groups.

For an age-specific definition of an inappropriate mean 24-h sinus heart rate in adolescents we used the data of the healthy control group who had a mean heart rate of 78.2 bpm with a double standard deviation of 16.8 bpm.

In summary, 74 adolescents had a mean 24-h heart rate ≥ 95 bpm, our cut-off for IST in adolescents. This cut-off is 5 bpm higher than that for adults with inappropriate sinus tachycardia. A logistic regression was performed to ascertain the effects of gender, congenital heart disease, attention deficit disorder, anorexia nervosa, short stature, constitutional thinness, obesity, hypertension, pre-hypertension on the likelihood that participants have IST. The model explained 11.0% (Nagelkerke R^2^) of the variance in IST and correctly classified 86.3% of cases. As shown in [Table 5](#pone.0238139.t005){ref-type="table"}, we found the risk of IST to be significantly high in adolescents with attention deficit disorder (OR = 3.5,p\<0.001), pre-hypertension (OR = 2.5, p = 0.043) and hypertension (OR = 2.1,p = 0.02); insignificantly enhanced in children with short stature (OR = 1.9,p = 0.19), surgically-treated congenital heart disease (OR = 1.4,p = 0.51) and obesity without hypertension (OR = 1.4;p = 0.25); and negligible in adolescents with anorexia nervosa (OR = 0.3, p = 0.26) and constitutional thinness (OR = 0.9,p = 0.89).

Of the 22 children with IST and attention deficit disorder, 13 formed part of the group of 69 children treated with methylphenidate, 6 formed part of the group of 7 children treated with atomoxetine, and 2 formed part of the group of 3 children treated with amphetamine.

These data suggest that IST in adolescents with attention deficit disorder is related to stimulant treatment, with the strongest association being to atomoxetine and amphetamine treatment. However, when we analyzed the effect of methylphenidate treatment on 24-h HRV in 19 adolescents, using data based on two Holter ECGs measured across a mean interval of 283 days after starting methylphenidate (N = 11) or stopping an ongoing therapy (N = 8), the mean 24-h heart rate of 91.3 ± 7.5 bpm remained unchanged with methylphenidate treatment at 91.9 ± 8.0 bpm ([Table 3](#pone.0238139.t003){ref-type="table"}). This surprising result indicates that the well-known heart rate increase after the daytime administration of methylphenidate from 96.0 ± 8.3 to 101.8 ± 10.8 bpm (p = 0.020) was completely compensated for by an equal heart rate decrease at night from 86.7 ± 9.7 to 82.4 ± 9.0 bpm. This effect on the circadian heart rate pattern is illustrated in [Fig 1](#pone.0238139.g001){ref-type="fig"}.

![Effects of Methylphenidate treatment on circadian heart rate in 19 adolescents.\
We prescribed omega-3 fatty acid supplementation and patients complied in 29 of the 74 adolescents with inappropriate sinus tachycardia, as shown in [Table 4](#pone.0238139.t004){ref-type="table"}, and we found highly significant effects on heart rate both by day and at night. The significant heart rate decrease of 8.3 bpm over 24 h, 6.6 bpm in daytime, and 11.7 bpm at night, related to a significantly higher HRV. Significantly higher RMSSD, pNN50, and high-frequency power values indicate a higher vagus activity after omega-3-fatty acid supplementation. However, as shown in other studies \[[@pone.0238139.ref006]\], omega-3-fatty acid supplementation improves HRV across the whole power spectrum of the Fast Fourier Analysis with nearly no effect on the HF/LF ratio. This could be an evidence of a specific effect of omega-3 fatty acid supplementation in children with autonomic dysfunction that not only depends on the autonomic system but also upon its effect on specific ion channels of the sinoatrial node.](pone.0238139.g001){#pone.0238139.g001}

We tested the impact of anthropometric measurements and HRV on the systolic blood pressure percentile using a linear regression analysis. The body mass index standard SDS value and the mean 24-h NN interval (heart rate = 60000/NN interval) were used to determine the systolic blood pressure percentile ([Table 6](#pone.0238139.t006){ref-type="table"}). The inclusion of the vagus parameter, RMSSD, and the global HRV parameter, SDNN, slightly improved this model, but not the frequency domain analysis. The impact of the heart rate (or NN Interval) on systolic blood pressure was the same for daytime or nighttime heart rates.

Discussion {#sec009}
==========

IST is a common cardiovascular risk factor in adolescence--74 of 479 (15.4%) adolescents in the current study had an elevated 24-h heart rate ≥ 95 bpm. At first, this result appeared to be related to the high use of psychostimulants (N = 79) in adolescents with attention deficit disorder. However, our data indicate that methylphenidate did not increase 24-h heart rates in 19 of 69 adolescents who had a Holter ECG with and without methylphenidate. This surprising result indicates that the well-known heart rate increase after daytime administration of methylphenidate from 96.0 ± 8.3 to 101.8 ± 10.8 bpm (p = 0.02) is completely compensated for by an equal heart rate decrease at night from 86.7 ± 9.7 to 82.4 ± 9.0 bpm, probably due to vagus activation with significantly higher RMSSD and pNN50 values.

Elevated heart rates, at least in adolescents with attention deficit disorder, seems to be a result of a genuine autonomic dysfunction with significantly reduced HRV. The risk of an IST is insignificant in children with surgically-treated congenital heart disease, short stature and obesity without arterial hypertension, and is negligible in adolescents with anorexia nervosa and constitutional thinness ([Table 5](#pone.0238139.t005){ref-type="table"}).

We found significantly reduced heart rates and blood pressures in adolescents with anorexia nervosa, but not in adolescents with constitutional thinness, despite the same average body mass index (Tables [1](#pone.0238139.t001){ref-type="table"} and [2](#pone.0238139.t002){ref-type="table"}). As we anticipated, caloric intake had an effect on both HRV and blood pressure, with low caloric intake inducing low heart rates and hypotension in individuals with anorexia nervosa and high caloric intake inducing high heart rates and hypertension in obese adolescents. We further found that children with constitutional thinness had normal caloric intake and normal heart rates and blood pressures (Tables [1](#pone.0238139.t001){ref-type="table"} and [2](#pone.0238139.t002){ref-type="table"}). Calorie reduction is probably the most effective treatment for reducing elevated heart rates and blood pressures in obese patients.

Linear regression analysis in the full cohort of 479 adolescents, clearly showed that the systolic blood pressure percentile depends primarily on the body mass index and mean 24-h heart rate. This result is in good accordance with the data from adults with IST who had a high risk of arterial hypertension. In summary, the more established cardiovascular risk factor, arterial blood pressure, and elevated mean heart rate probably predict cardiovascular risk. Our observations concur with those of the Swedish register data which showed that an elevated resting heart rate in adolescence is an important cardiovascular risk factor for later all-cause mortality primarily due to the higher risk of heart failure. Resting heart rate is independently associated with longevity, even when familial factors are controlled, such as in twin studies \[[@pone.0238139.ref011]\].

We investigated potential treatments for adolescents with IST with heart rates ≥ 95 bpm. We stopped psychostimulants in some children with attention deficit disorder, but this seems to be effective only in adolescents treated with atomoxetine and amphetamine and not in adolescents treated with methylphenidate. Much more effective was the omega-3-fatty acid supplementation of 29 adolescents with inappropriate sinus tachycardia, who showed a significant heart rate decrease by 8.3 bpm over 24 h, 6.6 bpm at daytime, and 11.7 bpm at night, together with significantly higher HRV. We did not systematically measure blood pressures after omega-3-fatty acid supplementation, but the effect on hypertension seems to be lower than that on heart rate.

After exclusion of hypertension in obese children, the remaining 53 adolescents with arterial hypertension had normal body mass indices and heart rate variabilities. Most of these adolescents received pharmacotherapy to treat hypertension. Patients with pre-hypertension had normal HRVs on average and probably no longer needed pharmacotherapy but only 24-h blood pressure monitoring.

Adolescents with surgically-treated congenital heart disease had nearly normal HRVs probably due to the close monitoring and pharmacotherapy with beta blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor antagonists.

Children with short stature due to small gestational age, syndromes, heart defects, and growth hormone deficiency, but not due to constitutional growth delay, had a reduced HRV as recently published \[[@pone.0238139.ref003]\]. There is no additional information in the current analysis.

We are aware that there are many open questions regarding the pathophysiology of IST as discussed in the literature \[[@pone.0238139.ref012]\]. We currently doubt our own hypothesis that the changes of HRV in children with IST are an expression of an autonomic imbalance between sympathicus and vagus. These very sophisticated considerations are not included in this publication written for clinicians. Instead we refer the reader to our current open access publication \[[@pone.0238139.ref013]\]. The question is if the reduced HRV in adolescents with IST across the whole power spectrum of the Fast Fourier Analysis with nearly no changes of the HF/LF ratio, not only depends on the autonomic system, but upon changes of the ion channels of the sinoatrial node. This important pathophysiological consideration may explain why omega-3 fatty acids as well as unusual channel blockers, like ivabradine, are even more effective in the treatment of IST than beta blockers.

Study limitations {#sec010}
-----------------

We divided this large patient group into many (not mutually disclosing) groups according diagnosis, height, body mass index and blood pressure. This methodological problem was part of the reviewing process. We included a binary logistic regression analysis which considers all diagnoses of the patients we examined and gives us the opportunity to declare odds ratios for the risk of IST.

This is a retrospective analysis including Holter ECG's from 2005. During these 15 years, we realized the impact of nutrition and omega-3-fatty acid supplementation on heart rate variability. The multiple individual therapeutic decisions cannot be a part of this publication. We focus on methylphenidate therapy in ADHD and omega-3-fatty acid supplementation in autonomic dysfunction. Due to the authors\`specialisation in pediatric cardiology, nearly all children had in part multiple ECG and echocardiographies that are not analyzed for this publication. The reader may be certain that none of the patients have an unrecognized heart disease.

We collected the raw data and we were able to transfer new methodological knowledge to older data sets. Today, we emphasize the importance of the mean heart rate, especially when it comes to risk assessment of cardiovascular endpoints. Heart rate significantly influences HRV due to both physiological and mathematical reasons. Moreover, physicians understand the heart rate much better than the sometimes-complicated method of HRV analysis. We try to sensitize pediatricians to the problem of heart rate regulation like inappropriate sinus tachycardia and offer an easily understandable cut off 95 bpm in adolescence.

However, the retrospective nature of the study--especially regarding omega-3-fatty acid supplementation--is a strong risk factor for "regression to the mean" as confounding mechanism. Moreover, a selection bias in children who got omega-3-fatty acid supplementation lies on the fact that their parents self-select themselves for the treatment, prove a higher motivation for the therapy and remain susceptible to a placebo effect. This means that the results of our analysis are hypothesis generating and deserve further exploration in a randomized control study.
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4\. Methods/Results/Figure 1: Please report how the IST risk was calculated. It seems like the depicted risk represents the percentage/prevalence of IST cases in each group (e.g. 22/86=26% for ADD). However, as described in point 1 this is unadjusted for BP/BMI/height and could be misleading. For example since those with obesity and ADD had high BP, we do not know to what extent BP could bias these findings.

5\. Results/Limitations: Omega-3-fatty acid supplementation was up to the patient\`s choice. Therefore a selection bias could confound the effect of supplementation. Additionally, since IST has been also associated with psychosocial distress, a strong placebo effect could partially account for the same effect. Please compare baseline characteristics of those who choose supplementation vs. those who did not and comment accordingly in the limitations section.
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1\. Methods: Indeed, dividing our patients into many groups with a broad overlap leads to important methodological problems. We performed a binary logistic regression analysis as proposed by reviewer 1. Heavy work - but a significant improvement of our publication. We deleted Figure 1 due to the misleading interpretation based on IST percentages in the diagnosis groups. We included a new table 5 with the results of the binary logistic regression analysis. The new results according to the Odds ratios are declared in the abstract:

"We found the risk of IST to be high in adolescents with attention deficit disorder (OR=3.5,p\<0.001), children with short stature (OR=1.9,p=0.19) and hypertension (OR=2.1,p=0.02); lower in surgically-treated congenital heart disease (OR=1.4,p=0.51) and obesity without hypertension (OR=1.4;p=0.25); and negligible in adolescents with anorexia nervosa (OR=0.3, p=0.26) and constitutional thinness (OR=0.9,p=0.89).

2\. " We explain the collection of the healthy control group and the citation of the published data and the ethic approvement (Reference 8).

3\. Results: We include a new table with the number and percentage of each diagnosis as supplement to our publication (Tablediagnosisgroups).

4\. See Point 1

5\. In a new statistic we compare adolescents who received Omega-3-FA with those who received no Omega-3-FA and found no significant group difference. Supplement to our publication (TableOmega3).

6\. The HF/LF ratios are calculated and included in table 3&4.

7\. The p-values are given as \<0.001 instead of a zero

8\. See study limitations
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1\) The diagnosis of IST seems to be based only on a single 24-h Holter 12-bit digital ECG. More measurements would have been more appropriate for a better diagnosis. Please report it in the limitation of the study.

2\) Any information about the clinic follow-up of these patients has been reported. If it is possible, follow-up data should be included.

3\) ECG, echocardiographic or anamnestic information is not be included in the analysis. This is an important limitation for this study.

4\) The tables should be improved and integrated with for clinical information of the patients.
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1\. IST depends on definition based upon the mean 24 hour heart rate \>90 bpm or daily heart rates \>100 bpm in adults. We adapt this definition to adolescents based upon our normal values. This definition was proofed in each patient.

2\. We focused the follow up on a second Holter ECG according to pharmacologic or nutritional intervention with methylphenidate therapy or omega-3-fatty acid supplementation. That's a lot for the first big study to inappropriate sinus tachycardia in childhood. Some authors frighten that the current paper is just overwhelmed. Calculating further follow up data would weaken the statistical power.

3\. Nearly all patients had ECG and echocardiographic data to exclude or proof heart defects or cardiomyopathies (see limitations).

4\. We include a supplement (Tablediagnosisgroups) that declare the individual diagnosis and percentages of IST, Obesity, Short Stature and hypertension. The Editor should decide weather to include this data as a 7th table in the original publication.
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General comments:

This is a revised manuscript about a retrospective study evaluating 479 children for the association of inappropriate sinus tachycardia (IST, n=79) with heart rate variability (HRV) in Holter-ECG. Healthy controls (n=66) are compared to 8 different groups with attention deficit disorder (ADD, n=86), obesity (n=130), short stature (n=15), congenital heart disease (n=55), anorexia nervosa (n=34), constitutional thinness (n=20), hypertension (n=53) or pre-hypertension (n=13). IST risk was higher in adolescents with attention deficit disorder (OR=3.5,p\<0.001), hypertension (OR=2.1,p=0.02) and pre-hypertension, but did not reach statistical significance in other groups. IST was associated with decreased HRV and omega-3-fatty acid supplementation was associated with decreased HR and increased HRV in adolescents with IST.

The authors are commended for sharing their data and for their efforts on the revision of the manuscript. The statistical methods have significantly improved. The interpretation and discussion of the results though should appropriately address some limitations:

Specific comments:

1\. Methods: Thank you for using logistic regression. Please notice that for the groups that the effect did not reach a statistical significance there is not enough evidence for an association. As such it is not correct to claim that IST risk was slightly increased in children with short stature 32 (OR=1.9,p=0.19), surgically-treated congenital heart disease (OR=1.4,p=0.51) and obesity 33 without hypertension (OR=1.4;p=0.25). The confidence interval of the ORs reveals the spread of that probability and why the p value is not significant. Interestingly, pre-hypertension (OR 2.5, p=0.04) reached significance but was not commented. Please correct accordingly the text/claims in the results and discussion sections.

2\. Methods: The authors report that patients with IST who got omega-3-fatty acid supplementation (N=29) and those who received no supplements (N=45) did not differ in their baseline parameters, but the table "Omega3" shows higher systolic blood pressure (77±26 vs. 76±30 mmHg, p=0.03) for the supplement group. This is interesting, especially since the no-supplement groups got mostly beta-blockers and had hypertension or congenital heart disease. Thus, hypertension could bias the results of the omega-3 supplementation. Did all 29+45 patients have a follow-up Holter? All after 196 days? Please comment (and correct the structure of the table; every comparison has a P value, what is the 2nd P value?)

3\. Discussion: The authors report that "elevated heart rates, at least in adolescents with attention deficit disorder, is a result of a genuine autonomic dysfunction with significantly reduced HRV". Before one assumes causality has to acknowledge the alternative explanations. Could Methylphenidate (stimulant medication) be the reason for the increased heart rate that in term leads to a reduced HRV? Please comment appropriately in the Discussion/Limitations section.

4\. Limitations: The selection bias in those who got omega-3-fatty acid supplementation lies on the fact that they self-select themselves for the treatment, prove a higher motivation for changes/therapy and remain susceptible to a placebo effect. This is a major limitation that should be mentioned in text for the readers along with weather their medication (Methylphenidate) changed along with the omega-3 supplements.

5\. Limitations: The retrospective nature of the study, especially in regard to omega-3 supplementation with IST (where increased heart rate is a selection criterion), introduces a strong risk for "regression to the mean" as confounding mechanism. This means that the results of this analysis are hypothesis generating and deserve further exploration in a randomized control study.

Reviewer \#2: The manuscript seems to be improved. It would be interesting following these young-patients during the growth.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

2 Aug 2020

Dear Editor,

Thank you again for the careful review of our manuscript.

The specific comments of Reviewer\#1 are included in our revision:

1\.

Indeed, the Odds ratios are not significantly elevated in the kids with short stature, congenital heart disease and obesity without hypertension -- we correct the text. Hypertension and prehypertension are significantly more common in kids with inappropriate sinus tachycardia. This fact is in good accordance with data from adults (1) and underline that inappropriate sinus tachycardia is an important cardiovascular risk factor.

2\.

We proof this table and the statistics that is part of the supplement and not the original publication. There is only a slight difference in the diastolic blood pressure percentile. Furthermore, we demonstrate the absolute blood pressure values and there is only a difference of 2.9 mmHg systolic blood pressure and 5.2 mmHg diastolic blood pressure. I declare this difference in the publication, but I cannot imagine that this is a real bias. I improve this table and delete the two tailed p-values.

Children who didn't receive omega-3-fatty acids had no follow-up Holter ECG, except those who need a pharmacotherapy.

3\.

The question if methylphenidate treatment is the cause of inappropriate sinus tachycardia in children with attention deficit disorder is very important and our first hypothesis. That is the reason why we test the kids with and without methylphenidate in a second Holter ECG. To our big surprise that is not the case as shown in table 3 (heart rate : 91.3 ± 7.5 bpm versus 91.9 ± 8.0 bpm). This is a very good information for millions of children who are treated with methylphenidate. To the best of our knowledge, we are the first who proof this hypothesis as everybody thinks that methylphenidate increases the heart rate as shown in the studies with single measurement after methylphenidate intake.

4 + 5.

We change the paragraph study Limitations:

Study Limitation

We must divide this large patient group into many (not mutually disclosing) groups according diagnosis, height, body mass index and blood pressure. This methodological problem was part of the reviewing process. We include a binary logistic regression analysis which considers all diagnoses of the patients we examined and give us the opportunity to declare odds ratios for the risk of IST.

This is a retrospective analysis including Holter ECG's from 2005. During these 15 years, we realize the impact of nutrition and omega-3-fatty acid supplementation on heart rate variability. The multiple individual therapeutic decisions cannot be a part of this publication. We focus on methylphenidate therapy in ADHD and omega-3-fatty acid supplementation in autonomic dysfunction. As pediatric cardiologists, nearly all children had in part multiple ECG and echocardiographies that are not analyzed for this publication. The reader may be certain that none of the patients have an unrecognized heart disease.

We collect the raw data and we were able to transfer new methodological knowledge to older data sets. Today, we emphasize the importance of the mean heart rate, especially when it comes to risk assessment of cardiovascular endpoints. Heart rate significantly influences HRV due to both physiological and mathematical reasons. Moreover, physicians understand the heart rate much better than the sometimes-complicated method of HRV analysis. We try to sensitize pediatricians to the problem of heart rate regulation like inappropriate sinus tachycardia and offer an easily understandable cut off 95 bpm in adolescence.

However, the retrospective nature of the study -- especially regarding omega-3-fatty acid supplementation -- is a strong risk factor for "regression to the mean" as confounding mechanism. Moreover, a selection bias in children who got omega-3-fatty acid supplementation lies on the fact that their parents self-select themselves for the treatment, prove a higher motivation for the therapy and remain susceptible to a placebo effect. This means that the results of our analysis are hypothesis generating and deserve further exploration in a randomized control study.

Yours sincerely

Prof. Dr. Reiner Buchhorn and Dr. Christian Willaschek

1\. Still AM, Raatikainen P, Ylitalo A, Kauma H, Ikäheimo M, Antero Kesäniemi Y, and Huikuri HV. Prevalence, characteristics and natural course of inappropriate sinus tachycardia. Europace 7: 104-112, 2005.
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PONE-D-20-09485R2

Dear Dr. Willaschek,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Antonio Cannatà

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: This is a revised manuscript about a retrospective study evaluating 479 children for the association of inappropriate sinus tachycardia (IST, n=79) with heart rate variability (HRV) in Holter-ECG. Healthy controls (n=66) are compared to 8 different groups with attention deficit disorder (ADD, n=86), obesity (n=130), short stature (n=15), congenital heart disease (n=55), anorexia nervosa (n=34), constitutional thinness (n=20), hypertension (n=53) or pre-hypertension (n=13). IST risk was higher in adolescents with attention deficit disorder (OR=3.5,p\<0.001), hypertension (OR=2.1,p=0.02) and pre-hypertension, but did not reach statistical significance in other groups. IST was associated with decreased HRV and omega-3-fatty acid supplementation was associated with decreased HR and increased HRV in adolescents with IST.

The authors are commended for the revision. Their efforts are highly appreciated and the manuscript has significantly improved. Thank you and congratulations!

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No
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Diagnosis and management of an inappropriate sinus tachycardia in adolescence based upon a Holter ECG: A retrospective analysis of 479 patients

Dear Dr. Willaschek:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Antonio Cannatà

Academic Editor

PLOS ONE
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